Substance / Medication

Nonacog alfa

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Hemophilia A

Factor VII deficiency

Hemophilia B

Factor IX deficiency

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities.

Rendo Pablo, Smith Lynne, Lee Hsiao-Yu et al. · Blood Coagul Fibrinolysis · 2015

PMID: 26196195Meta-Analysis

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.

Collins P W, Quon D V K, Makris M et al. · Haemophilia · 2018

PMID: 28833808RCT

Performance of a Drug-Specific Calibration Curve for Monitoring Treatment With Albutrepenonacog Alfa: A Multicenter Study in Argentina.

Martínez Pablo, Arrieta María Verónica, Detarsio Germán Alejandro et al. · Int J Lab Hematol · 2025

PMID: 40176382Observational

Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B.

Fukutake Katsuyuki, Taki Masashi, Matsushita Tadashi et al. · Haemophilia · 2019

PMID: 31168882ObservationalFull text (PMC)

A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.

Berntorp E, Keeling D, Makris M et al. · Haemophilia · 2012

PMID: 22044794Observational

Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa (rIX-FP): A case report.

López-Jaime Francisco José, Fernández-Bello Ihosvany, Calavia-Aranda Eva et al. · Clin Case Rep · 2023

PMID: 37323270Case ReportFull text (PMC)

Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case Series.

Nagao Azusa, Bingo Masato, Yamaguchi Tomoko et al. · Cureus · 2023

PMID: 36779089Case ReportFull text (PMC)

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management.

Benitez Hidalgo Olga, Martinez Garcia M Fernanda, Bescos Cabestre Agustin et al. · Clin Case Rep · 2022

PMID: 35620255Case ReportFull text (PMC)

Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain.

Rodríguez López Manuel, Megías Vericat Juan Eduardo, Albo López Carmen et al. · BMJ Case Rep · 2020

PMID: 33051199Case ReportFull text (PMC)

Measurements of eftrenonacog alfa by 19 different combinations reagents/instrument: A single-centre study.

Sinegre Thomas, Trayaud Adeline, Tardieu Maryse et al. · Haemophilia · 2020

PMID: 32314511Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Nonacog alfa (substance)
SNOMED CT: 425189006
UMLS CUI: C2826076

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.